DARATUMUMAB
daratumumab 100 mg/5 mL injection, 5 mL vial
DARATUMUMAB (12226L)
12226L
Manner of administration:Injection
Restriction
Indication: Relapsed and/or refractory multiple myeloma
Treatment phase: Continuing treatment of second-line drug therapy from week 25 until disease progression
(administered every 4 weeks)
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 1920 mg | # of repeats: 5 | DPMA: $11,391.90 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Darzalex
(daratumumab 100 mg/5 mL injection, 5 mL vial)
|
||||
| Darzalex
(daratumumab 400 mg/20 mL injection, 20 mL vial)
|
||||